S. Bartfay
Sahlgrenska University Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S. Bartfay.
The Journal of Thoracic and Cardiovascular Surgery | 2017
S. Bartfay; Göran Dellgren; Hans Lidén; Mikael Holmberg; Jakob Gäbel; Bengt Redfors; Odd Bech-Hanssen; Kristjan Karason
Objective: Right ventricular failure in patients treated using left ventricular assist devices is associated with poor outcomes. We assessed the strategy of preplanned biventricular assist device implantation in patients with a high risk for right ventricular failure. Methods: Between 2010 and 2014, we assigned 20 patients to preplanned biventricular assist device and 21 patients to left ventricular assist device as a bridge to heart transplantation on the basis of the estimated risk of postimplant right ventricular failure. Preimplant characteristics and postimplant outcomes were compared between the 2 groups. Results: Patients with a biventricular assist device were younger, more often female, and more frequently had nonischemic heart disease than left ventricular assist device recipients. At preoperative assessment, biventricular assist device recipients had poorer Interagency Registry for Mechanically Assisted Circulatory Support profiles, a lower cardiac index, and more compromised right ventricular function. Survival on device to heart transplantation/weaning/destination for biventricular assist device and left ventricular assist device recipients was 90% versus 86% (not significant), with shorter heart transplantation waiting times for biventricular assist device recipients (median days, 154 vs 302, P < .001). Overall survival at 1 year was 85% (95% confidence interval, 62‐95) versus 86% (95% confidence interval, 64‐95) (not significant). The majority of both biventricular assist device and left ventricular assist device recipients could be discharged to home during the heart transplantation waiting time (55% vs 71%, not significant), and complication rates on device were comparable between groups (major stroke 10% vs 10%, not significant). Conclusions: Planned in advance, the biventricular assist device seems to be a feasible option as bridge to heart transplantation for patients with a high risk of postimplant right ventricular failure. The outcomes for these patients were similar to those observed for contemporary left ventricular assist device recipients, despite those receiving biventricular assist devices being more severely ill.
International Journal of Cardiology | 2017
Göran Dellgren; Andreas Westerlind; Hans Liden; Jakob Gäbel; S. Bartfay; Entela Bollano; Erik Holmberg; Bert Andersson; Henrik Scherstén; Kristjan Karason
AIMS Heart transplantation (HTx) has become the standard treatment for patients with end-stage heart disease. We report on the long-term outcome after HTx at our centre and investigate trends in outcome over time. METHODS During the period, between 1984 and 2014, a total of 610 HTx procedures were performed in 595 patients (median 48years; IQR 31-57years; range 24days-71years; mean 43years; 75% male) in our institution. Long-term outcome was investigated in the whole cohort, among children (n=76), bridged with mechanical circulatory support (MCS, n=131), re-transplanted (n=17), and concomitant kidney transplantation (n=12). RESULTS Long-term survival was at 1, 5, 10, 15 and 20years: 86% (95CI 0.83-0.89); 77% (95CI 0.73-0.80); 63% (95CI 0.59-0.68); 48% (95CI 0.43-0.54) and 30% (95CI 0.25-0.36), respectively. The median survival for the whole cohort was 14.1years. Patients transplanted during the most recent time period (2010-2014) had a better survival compared to previous eras, with a 1- and 3-year survival of 94% (95CI 0.89-0.97) and 93% (95CI 0.88-0.96), respectively (p<0.001). However, when survival was analysed for long-term MCS (n=80) versus short term MCS (n=35), there was a significantly poorer survival for the short-term MCS group (p=0.001). Independent predictors of long-term mortality included recipient age (p=0.041); previous smoking (p=0.034); ischemic heart disease (p=0.002); and preoperative ventilator therapy (p=0.004). CONCLUSIONS We have shown that continuous improvement in outcome after HTx still occurs. In the last time era, direct transplantation from short-term MCS was abandoned, which may have inflicted outcome during the last time era.
European Heart Journal | 2013
S. Bartfay; Hans Liden; Mikael Holmberg; Kristjan Karason; Jakob Gäbel; N. Selimovic; Göran Dellgren
Journal of Heart and Lung Transplantation | 2014
S. Bartfay; Lars Gullestad; Vilborg Sigurdardottir; Arne K. Andreassen; Einar Gude; Bert Andersson
Journal of the American Heart Association | 2018
Lukas Lannemyr; Sven-Erik Ricksten; Bengt Rundqvist; Bert Andersson; S. Bartfay; Pia Dahlberg; Niklas Bergh; Clara Hjalmarsson; Thomas Gilljam; Entela Bollano; Kristjan Karason
Journal of Heart and Lung Transplantation | 2018
Kristjan Karason; L. Lannemyr; Bengt Rundqvist; Bert Andersson; S. Bartfay; C. Ljungman; P. Dahlberg; N. Bergh; Clara Hjalmarsson; T. Gilljam; Entela Bollano; Sven-Erik Ricksten
Journal of Heart and Lung Transplantation | 2018
S. Bartfay; Göran Dellgren; P. Dahlberg; S. Hallhagen; B. Redfors; Kristjan Karason
Journal of Heart and Lung Transplantation | 2016
Entela Bollano; Kristjan Karason; Clara Hjalmarsson; S. Bartfay; B. Daka; Bert Andersson; Göran Dellgren
Journal of Heart and Lung Transplantation | 2016
Göran Dellgren; Hans Liden; S. Bartfay; Sven-Erik Ricksten; Jakob Gäbel; Helena Rexius; E. Bolano; Kristjan Karason
Journal of Heart and Lung Transplantation | 2015
S. Bartfay; Hans Liden; Mikael Holmberg; Kristjan Karason; Jakob Gäbel; B. Redfors; Göran Dellgren